Common Variable Immunodeficiency Clinical Trial
Official title:
A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID)
Verified date | September 2012 |
Source | CSL Behring |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The objectives of this trial are the assessment of safety and efficacy of IgPro10 in patients with PID, and the assessment of tolerability of high infusion rates. To demonstrate safety, the number of infusions temporally associated with AEs, the rate, severity and relationship of all AEs and the vital sign changes during each infusion will be evaluated.
Status | Completed |
Enrollment | 55 |
Est. completion date | April 2008 |
Est. primary completion date | April 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 4 Years to 71 Years |
Eligibility |
Key Inclusion Criteria: Patients with CVID (Common Variable Immunodeficiency) or XLA (X-linked agammaglobulinemia) who: Participated in the Phase III clinical study with intravenous IgPro10 (study number ZLB03_002CR) at 3- or 4- weekly intervals for 12 months (referred to as 'old' subjects) OR Were = 6 years of age, were on other stable intravenous immunoglobulin therapy (200-800 mg IgG per kg body weight) at 3- or 4-week intervals for at least 6 months, AND were interested in participating in the Phase III clinical study with subcutaneous IgPro20 (study number ZLB04_009CR) (referred to as 'new' subjects) Written informed consent Key Exclusion Criteria: Diagnosis of epilepsia Insulin dependent diabetes Administration of steroids (daily = 0.15 mg prednisone equivalent/kg/day) or other immunosuppressive drugs History of cardiac insufficiency (NYHA III/IV), cardiomyopathy, congestive heart failure, severe hypertension |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Contact CSL Behring for facility details | Centennial | Colorado |
United States | Contact CSL Behring for facility details | Dallas | Texas |
United States | Contact CSL Behring for facility details | Fort Wayne | Indiana |
United States | Contact CSL Behring for facility details | Indianapolis | Indiana |
United States | Contact CSL Behring for facility details | Iowa City | Iowa |
United States | Contact CSL Behring for facility details | Los Angeles | California |
United States | Contact CSL Behring for facility details | North Palm Beach | Florida |
United States | Contact CSL Behring for facility details | Rochester | Minnesota |
United States | Contact CSL Behring for facility details | St. Louis | Missouri |
United States | Contact CSL Behring for facility details | St. Petersburg | Florida |
Lead Sponsor | Collaborator |
---|---|
CSL Behring |
United States,
Sleasman JW, Duff CM, Dunaway T, Rojavin MA, Stein MR. Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates. J Clin Immunol. 2010 May;30(3):442-8. doi: 10.1007/s10875-010-9373-x. Epub 2010 Mar 10. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Proportion of Infusions With One or More Temporally-associated Adverse Events (AEs). | AEs were considered temporally-associated AEs if they occurred during the infusion or in the period from the start of the infusion until either 48 or 72 hours after the end of the infusion. | During each infusion, and within 48 or 72 hours after the end of each infusion. | Yes |
Primary | Influence of Infusion Rate on Temporally-Associated AEs | The total and most frequent (1% or more) number of infusions for which subjects experienced temporally-associated AEs occurring within 72 hours of infusion, by infusion rate (= 4 mg/kg/min, = 8 mg/kg/min, and > 8 and = 12 mg/kg/min). AEs were considered to be temporally-associated AEs if they occurred in the period from the start of the infusion until 72 hours after the end of the infusion. |
Within 72 hours after each infusion | Yes |
Primary | Rate of AEs by Severity and Relationship | The AE rate was the number of AEs over the number of infusions administered. Mild AEs: Did not interfere with daily activities; Moderate AEs: Interfered with routine daily activities; Severe AEs: Impossible to perform routine daily activities. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs. |
For the duration of the study, up to approximately 29 months | Yes |
Primary | Number of Subjects With Clinically Significant Changes in Vital Signs. | Vital signs included heart rate, systolic blood pressure, diastolic blood pressure, and body temperature. | Before, during, and after each infusion. | Yes |
Secondary | Annualized Rate of Acute Serious Bacterial Infections. | The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Acute serious bacterial infections included pneumonia, bacteremia / septicemia, osteomyelitis / septic arthritis, bacterial meningitis, and visceral abscess. |
For the duration of the study, up to approximately 29 months | No |
Secondary | Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Illness. | For the duration of the study, up to approximately 29 months. | No | |
Secondary | Number of Days of Hospitalization. | For the duration of the study, up to approximately 29 months | No | |
Secondary | Annualized Rate of Any Infection. | The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Infections were classified as all AEs with the system organ class "infections and infestations" and AEs with the preferred term "conjunctivitis". |
For the duration of the study, up to approximately 29 months. | Yes |
Secondary | Trough Levels of Total Immunoglobulin (IgG) Serum Concentrations. | Mean IgG trough concentration. For this analysis, each subject's values were first aggregated to their median and the median values were then analyzed. | Prior to each infusion; every 3 or 4 weeks depending upon the dosing schedule. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03663933 -
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
|
Phase 2 | |
Recruiting |
NCT01652092 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
|
N/A | |
Recruiting |
NCT05321407 -
COVID-19 Vaccine Responses in PIDD Subjects
|
||
Recruiting |
NCT04339777 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
|
Phase 2 | |
Completed |
NCT00542997 -
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy
|
Phase 3 | |
Completed |
NCT00168025 -
Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
|
Phase 3 | |
Completed |
NCT00168012 -
Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)
|
Phase 3 | |
Completed |
NCT00004695 -
Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency
|
N/A | |
Completed |
NCT01196702 -
Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
|
||
Recruiting |
NCT06355323 -
Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France
|
N/A | |
Recruiting |
NCT02579967 -
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
|
Phase 2 | |
Recruiting |
NCT06145100 -
Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)
|
||
Completed |
NCT01289847 -
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
|
Phase 4 | |
Completed |
NCT00520494 -
Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
|
Phase 4 | |
Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
Completed |
NCT03211689 -
The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease
|
N/A | |
Terminated |
NCT01489618 -
"Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency
|
Phase 2 | |
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT03188419 -
Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide
|
||
Not yet recruiting |
NCT05481554 -
Composition and Function of Gut Microbiota in Porto-sinusoidal Vascular Disease Associated With Variable Common Immunodeficiency
|